YangC.S., HungK.C., HuangY.M., and HsuW.M.Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy. J. Ocul. Pharmacol. Ther., 29:550–555, 2013.
2.
YehP.T., YangC.M., LinY.C., ChenM.S., and YangC.H.Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina., 29:768–774, 2009.
3.
ZhaoL.Q., ZhuH., ZhaoP.Q., and HuY.Q.A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br. J. Ophthalmol., 95:1216–1222, 2011.
4.
SpaideR.F., and FisherY.L.Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina., 26:275–278, 2006.
5.
MeyerC.H., KrohneT.U., and HolzF.G.Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina., 31:1877–1884, 2011.
6.
AveryR.L., PearlmanJ., PieramiciD.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology., 113:1695–1705, 2006.
